United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
IPO Year: 1999
Exchange: NASDAQ
Website: unither.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
| 12/8/2023 | $309.00 | Overweight | Wells Fargo |
| 12/6/2022 | $320.00 | Buy | UBS |
| 12/5/2022 | $230.00 | Sell | Goldman |
| 10/11/2022 | $288.00 | Overweight | Morgan Stanley |
| 9/20/2022 | Underperform | BofA Securities |
Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight
BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00
Morgan Stanley downgraded United Therapeutics from Overweight to Equal-Weight and set a new price target of $321.00 from $310.00 previously
Goldman upgraded United Therapeutics from Sell to Neutral and set a new price target of $215.00 from $213.00 previously
Leerink Partners initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $330.00
Wells Fargo initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $309.00
UBS initiated coverage of United Therapeutics with a rating of Buy and set a new price target of $320.00
Goldman initiated coverage of United Therapeutics with a rating of Sell and set a new price target of $230.00
Morgan Stanley initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $288.00
BofA Securities reiterated coverage of United Therapeutics with a rating of Underperform
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025. At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting and Scientific Sessions taking place April 27 through April 30, 2025 in Boston. "The additional data across our portfolio presented at this year's meeting highlight our commitment to furthering the science and standards of care in pulmonary hypertension and progressing the future of xenotransplantation," said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. "We look forwa
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list. "We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For," said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. "This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Leerink Partners Global Healthcare Conference 2025 in Miami Beach. The session will take place on Tuesday, March 11, 2025, from 10:00 a.m. to 10:30 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 da
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company's operations during a fireside chat session at the TD Cowen 45th Annual Health Care Conference in Boston. The session will take place on Monday, March 3, 2025, from 1:50 p.m. to 2:20 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days. United Th
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics,
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line data expected in the first half of 2026 United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis (IPF). The TETON 1 study enrolled 598 patients and is part of the three-study global TETON clinical trial program evaluating the use of inhaled treprostinil in IPF and a similar condition, progressive pulmonary fibrosis (PPF). TETON 1 is e
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SD - UNITED THERAPEUTICS Corp (0001082554) (Filer)
SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer)
DEFA14A - UNITED THERAPEUTICS Corp (0001082554) (Filer)
DEF 14A - UNITED THERAPEUTICS Corp (0001082554) (Filer)
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
10-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics,
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3 billion annual revenue run rate in the third quarter," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of our stellar revenue performance, 2025 marks the start of a multi-year cascade of clinical data reads and r
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. "This quarter we drove record revenue from our foundational commercial business. Next year we expect data from our innovative clinical pipeline. All this while we march forward with our revolutionary organ manufacturing programs," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "We believe there is no other biotech with our combination of rel
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 31, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mi
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023. "The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth," jointly said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer and Michael Benkowitz, President and Chief Operating Officer. "That growth, coupled with our upcoming clinical reads, puts us in a unique position in the biotech industry: a company with a sol
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, May 1, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission